4577
Fiscal year ends May Quarters are offset from the calendar — Q1 is Jun–Aug

Daito Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the manufacturing, sales, and contract production of active pharmaceutical ingredients (APIs) and finished dosage forms, including prescription and over-the-counter drugs. The company operates a single business segment focused on pharmaceuticals, supplying APIs primarily to generic drug manufacturers and providing contract manufacturing services to major new drug developers. It maintains production capabilities compliant with Japanese GMP, FDA, and EMA standards, supporting both large-scale and small-batch, multi-variety production. The company does not employ medical representatives and partners with pharmaceutical manufacturers for the sales and promotion of its generic products. Its group structure includes subsidiaries and associates in the United States and China, such as Daito Pharmaceuticals America, Inc. and Daikou Pharmaceutical (China) Co., Ltd., which support export activities and regional market expansion.

Summarised from the annual report, fiscal year ended May 2026

Industry Drug Manufacturers - Specialty & Generic Homepage daitonet.co.jp
Sector Healthcare IR page daitonet.co.jp
Tags
active pharmaceutical ingredients, generic drugs, contract manufacturing, over-the-counter drugs, health foods, pharmaceutical formulation, Daito Pharmaceuticals America Inc., Daikou Pharmaceutical (China) Co. Ltd., Senki Pharmaceutical (Anhui) Co. Ltd., Anhui Dingwang Pharmaceutical Co. Ltd., Felsen Pharma Co. Ltd., Daiyo Pharmaceutical Industry Co. Ltd.
Press page daitonet.co.jp/news

Metrics

Valuation  
Market cap ¥ 37.944B
Market cap (USD) $ 237.154M
P/E 12.07
PEG —
P/BV 0.72
P/S 0.75
P/OCF 4.05
P/FCF 9.05
Dividend yield 3.0%
Turnover / mcap —
Returns  
ROE 6.0%
ROI 5.6%
ROIC 5.0%
Profit margin 6.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -4.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score 11.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 50.65B 50.643B 46.895B 45.101B 43.464B 48.715B 44.991B 41.135B 39.876B 37.984B 36.371B 34.059B 31.196B 28.956B
Net profit 3.161B 1.908B 3.295B 3.6B 4.668B 4.246B 3.945B 3.513B 3.042B 2.656B 2.566B 2.246B 1.811B 1.787B
Free cash flow 4.191B -1.133B -1.094B -1.401B -363M -1.167B 1.533B 3.225B 1.592B 2.078B -999.75M — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.201K 984.94 2.226K 2.303K 2.617K 3.281K 4.361K 3.366K 3.615K 2.241K 2.705K 2.631K 1.551K 1.332K
Price performance 12m 0.22 -0.56 -0.03 -0.12 -0.2 -0.25 0.3 -0.07 0.61 -0.17 0.03 0.7 0.16 —

Filed figures

Figure May 2017 May 2018 May 2019 May 2020 May 2021 May 2022 May 2023 May 2024 May 2025 May 2026
Balance sheet detail
Trade receivables (JPY) 13.6B 13.1B 12.2B 15.5B 12.8B 16.1B 17.6B 15.4B 20.2B 18.9B
↳ YoY growth +5.5% -3.4% -7.2% +27.5% -17.8% +26.1% +9.5% -12.7% +31.1% -6.3%
↳ 5y CAGR -0.2% +3.5% +6.1% +4.8% +5.4% +8.2%
Borrowings, current (JPY) 4.8B 3.37B 1.85B 1.51B 1.36B 1.19B 1.43B 2.1B 3.1B 2.82B
Borrowings, non-current (JPY) 3.69B 4.02B 3.09B 1.58B 2.02B 2.25B 3.37B 4.67B 6.57B 3.75B
Lease liabilities (JPY) 32.4M 17.5M 9.13M 4.5M 1.5M — 92M 1.95B 2.22B 2.73B
Cash and deposits (JPY) 1.62B 1.71B 1.82B 3.08B 3.37B 4.38B 3.61B 2.73B 2.21B 954M
Intangible assets (JPY) 322M 330M 307M 299M 333M 386M 377M 490M 531M 1.71B
Net debt (borrowings + leases - cash) (JPY) 6.91B 5.69B 3.14B 14M 9.78M -945M 1.28B 5.99B 9.68B 8.34B
Cash flow detail
Operating cash flow (JPY) 5.07B 5.47B 6.89B 4.31B 5.18B 4.37B 4.16B 5.18B 5.9B 9.38B
Purchases of property, plant and equipment (JPY) -2.99B -3.82B -3.63B -2.73B -6.32B -4.63B -5.51B -6.22B -6.79B -3.82B
Purchases of intangible assets (JPY) — -51.6M -32.6M -42.1M -31.1M -106M -51M -56M -241M -1.37B
Change in receivables (cash effect) (JPY) -711M 458M 948M -3.37B 2.72B -3.3B -1.5B 2.22B -4.89B 1.33B
Change in inventories (cash effect) (JPY) -1.51B -815M -751M -2.08B -3.61B -1.04B -1.41B -2.64B 2.42B 2.02B
Change in payables (cash effect) (JPY) -90.5M 737M 335M 1.23B -765M 22M 538M 802M -360M -874M
Dividends paid (cash effect) (JPY) -375M -413M -451M -502M -658M -660M -931M -907M -998M -1.12B
Share buybacks (cash effect) (JPY) -670,000 -1.03M -442,000 -188,000 -283,000 0.00 -110M -1.18B -623M -1.63B
Interest paid (cash effect) (JPY) -28.5M -23.9M -20.5M -11.5M -7.58M -9M -13M -40M -126M -129M
Income taxes paid (cash effect) (JPY) -767M -1.68B -1.43B -811M -2.09B -1.92B -2.41B -1.27B -842M -729M
Operating cash flow before change in receivables (JPY) 5.78B 5.01B 5.94B 7.68B 2.46B 7.67B 5.66B 2.96B 10.8B 8.04B
Free cash flow (OCF - PPE - intangibles) (JPY) 2.08B 1.59B 3.23B 1.53B -1.17B -363M -1.4B -1.09B -1.13B 4.19B
Income detail
Research and development expense (JPY) 1.27B 1.52B 1.61B 1.4B 2.03B 1.75B 1.87B 2.35B 2.52B 2.22B
↳ 5y CAGR +11.6% +6.7% +4.1% +7.9% +12.5% +1.8%
Total comprehensive income (JPY) 2.53B 3.1B 3.3B 4.01B 3.91B 4.82B 4.04B 3.37B 1.38B 3.62B
Comprehensive income to owners (JPY) 2.58B 3.11B 3.33B 4.06B 3.97B 4.82B 4.11B 3.48B 1.51B 3.64B
Provision for credit losses (JPY) 897,000 2.68M — 128,000 — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.0% — 0.0% — — — — — —
Reported Aug 30, 2017 Aug 30, 2018 Aug 30, 2019 Aug 28, 2020 Aug 26, 2021 Aug 25, 2022 Aug 30, 2023 Aug 30, 2024 Aug 27, 2025 Aug 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Daito Pharmaceutical Co., Ltd. (ticker 4577), listed in Japan.

ETFs Holding Daito Pharmaceutical Co., Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.03% 179,153 $ 1.48M Nov 12, 2026
AVDV 0.01% 185,200 $ 1.552M Nov 16, 2026
AVDS 0.01% 2,820 $ 23.627K Nov 16, 2026
DXIV 0.01% 2,100 $ 17.349K Nov 12, 2026
DFIS 0.01% 48,460 $ 400.348K Nov 12, 2026
DFIC 0.00% 32,480 $ 268.331K Nov 12, 2026
DFAX 0.00% 21,716 $ 179.405K Nov 12, 2026
DFAI 0.00% 19,600 $ 161.924K Nov 12, 2026
AVDE 0.00% 16,160 $ 135.394K Nov 16, 2026